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Objectives, This study sought o analyze the health and eco- 
nomic outcomes of withdrawal of digoxin therapy among U.S. 
adult patients with stable congestive h art failure. 
Background. New information regarding the outcomes of 
digoxin withdrawal has been provided by the Prospective Ran- 
domized Study of Ventricular Failure and Efficacy of Digoxin 
(PROVED) and Randomized Assessment of Digoxin and Inhibitors 
of Angiotensin-Converting Enzyme (RADIANCE) trials. We inter- 
preted and extrapolated the results of these trials to describe 
implications on a national level. 
Methods. We used a decision-analytic model to estimate the 
outcomes of two alternative strategies to 1) continue and 2) 
withdraw digoxin in patients with congestive heart failure with 
normal sinus rhythm, New York Heart Association functional 
class II or III and left ventricular ejection fraction <35%. 
Epidemiologic assumptions were derived from published reports 
and expert opinion. Assumptions regarding the effectiveness of 
digoxin therapy were derived from the RADIANCE and PROVED 
digoxin withdrawal trials. Hospital and Medicare data were used 
for economic assumptions. Calculated outcomes included treat- 
ment failures, cases of digoxin toxicity and health care costs. 
Results. The continuation ofdigoxin therapy in these patients 
with congestive h art failure nationally would avoid an estimated 
185,000 clinic visits, 27,000 emergency visits and 137,000 hospital 
admissions for congestive heart failure. After accounting for an 
estimated 12,500 cases of digoxin toxicity, the net annual savings 
would be $406 million, with a 90% range of uncertainty of$106 to 
$822 million. One-way sensitivity analysis indicated that digoxin 
therapy is cost-saving when the assumed annual incidence of 
digoxin toxicity is <33%. 
Conclusions. The continuation of digoxin therapy in patients 
with stable congestive h art failure should be strongly considered, 
because this strategy is likely to lead to both lower costs and 
greater health benefits on the basis of available information. 
(J Am Coil Cardiol 1995;26:93-101) 
Although digitalis glycosides have been used to treat heart 
disease for >200 years (1), the role of digoxin therapy in adult 
patients with stable congestive heart failure who are in normal 
sinus rhythm remains controversial (2-5). Over the past few 
decades, randomized clinical trials have demonstrated that 
both digoxin and angiotensin-converting enzyme inhibitors 
improve left ventricular function (6-8) and prevent clinical 
deterioration (8) in patients with congestive heart failure. 
Although angiotensin-converting e zyme inhibitors have been 
shown to increase life expectancy (9-11), to our knowledge no 
study to date has attempted todemonstrate improved survival 
with digoxin. Little is known about he incidence or severity of 
toxicity resulting from outpatient digoxin therapy, but investi- 
gators subjectively addressing the trade-off between the bene- 
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fits and side effects of digoxin have suggested (4) that it is safe 
and prudent to discontinue digoxin in patients with mild, stable 
congestive heart failure. 
New information regarding this question has been provided 
by the Prospective Randomized Study of Ventricular Failure 
and Etficacy of Digoxin (PROVED) (12) and Randomized 
Assessment of Digoxin and Inhibitors of Angiotensin- 
Converting Enzyme (RADIANCE) (13) trials. These multi- 
center, double-blind, placebo-controlled digoxin-withdrawal 
trials, utilizing identical design variables, demonstrated that in 
patients with congestive heart failure who are (13) or are not 
receiving (12) angiotensin-converting e zyme inhibitors, contin- 
uation of digoxin therapy reduces the risk of treatment failures 
requiring changes in congestive heart failure therapy or result- 
ing in congestive heart failure-related emergency visits and 
hospital admissions. Our objective was to conduct a clinical 
policy analysis to 1) explicitly weigh the benefits, risks and costs 
of continuation of digoxin therapy and 2) evaluate the eco- 
nomic implications of digoxin withdrawal on a national level. 
Methods  
We utilized an approach to clinical policy analysis that was 
adapted from methods proposed by Eddy (14). In step 1, we 
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defined alternative policy proposals regarding the use of 
digoxin in adult patients with stable congestive heart failure. In 
step 2, we explicitly identified the important health and 
economic outcomes that are affected by the decision. In step 3, 
we estimated the magnitude of these outcomes under each of 
the alternative proposals. Step 4, which is left to the reader, is 
to select the alternative that would be preferred by the 
population of patients with congestive heart failure who gain 
the benefits, take the risks and ultimately bear the costs of 
medical interventions. 
The economic outcomes were calculated from the perspec- 
tive of the health care system. Modeling was done using a 
microcomputer-based electronic spreadsheet. The sources of 
uncertainty in the model results were evaluated using one-way 
sensitivity analysis for all model assumptions, varying each 
assumption across a predetermined range of reasonable sti- 
mates. The overall uncertainty ofmodel results was estimated 
using the Monte Carlo multiway sensitivity analysis approach 
(15). For the Monte Carlo simulation, assumptions based 
directly on the results of dichotomous outcome measurements 
from clinical trials were assigned values according to the 
binomial distribution. All other assumptions were assigned 
values according to a uniform distribution across the same 
predetermined range used for one-way sensitivity analysis. 
Policy alternatives compared. In step 1, we defined the 
population of patients with stable congestive h art failure who are 
currently receiving digoxin and identified two policy alternatives 
regarding the pharmacologic management of this group of pa- 
tients. For purposes of this analysis, we defined the "stable 
congestive heart failure" population as including any patient with 
normal sinus rhythm, a left ventricular ejection fraction -<35% 
and New York Heart Association functional class II (capable of 
conducting "usual activities," such as light yard work or sexual 
intercourse) or class III (capable of "self-care activities," such as 
dressing or making a bed) (16). Under the first policy alternative 
considered (plan A), we would withdraw digoxin therapy and 
resume digoxin only during episodes when the patient's condition 
was unstable. Under the second policy alternative (plan B), we 
would continue digoxin therapy, monitoring serum digoxin con- 
centration every 3 months, making appropriate adjustments in
dose and interval. 
Health and economic outcomes considered. In step 2, we 
identified health and economic outcomes hypothesized to change 
as a result of the selection of one of these policy alternatives. 
Continuation of digoxin therapy leads to the risks of digoxin 
toxicity. Digoxin offers the possible benefits of reduced congestive 
heart failure morbidity, leading to improved quality of life, and 
reduced congestive heart failure mortality. Because no clinical 
trials have had the power to detect any survival benefit of digoxin 
therapy among patients with stable congestive heart failure, we 
assumed that the drug had no effect on mortality. Although a 
number of studies, including the PROVED and RADIANCE 
trials, have demonstrated an effect of digoxin on various func- 
tional status or quality of life variables, we did not attempt to 
estimate the magnitude of this benefit, such as by calculating 
"quality-adjusted life years." We did, however, estimate the 
Table 1. Model Assumptions 
Assumed Values 
Low Baseline High 
Epidemiologic assumptions 
Prevalence of CHF in U.S. (16) 1,500,000 2,500,000 
Proportion of patients with 30% 50% 
CHF meeting criteria (EP) 
Proportion of patients with 26% 46% 
CHF taking ACE inhibitors 
(HFH) 
Baseline annual risk of hospital 0.150 
admissions (16) 
Baseline mergency visits as % 0.052 
of admissions (12,13) 
Baseline clinic visits/yr as % of 1.26 
admissions (12,13) 
Effectiveness a sumptions 
Annual incidence of digoxin 0.001 
toxicity (EP) 
Relative risk of Rx failure with 0.06 
ACE inhibitors, wk 1-12 
03) 
Relative risk of Rx failure 0.21 
without ACE inhibitors, wk 
1-12 (12) 
Effectiveness during wk 13-52 0.50 
relative to wk 1-12 (EP) 
Economic assumptions 
Cost of digoxin therapy/patient 40 60 
per yr (HFH) 
Cost of digoxin serum level 30 50 
monitoring/patient per yr 
(HFH) 
Cost of CHF hospital 3,500 3,844 
admissions (HFH) 
Cost of emergency department 250 363 
visit for CHF (HFH) 
Cost of physician visit (HFH) 50 100 
Cost to treat average pisode 500 1,000 
of digoxin toxicity (EP) 
0.216 
0.200 
1.350 
0.01 
0.23 
0.50 
0.75 
3,500,000 
75% 
66% 
80 
70 
0.250 
0.315 
1.84 
0.02 
0.47 
0.94 
1.00 
4,500 
50O 
200 
2,000 
Numbers in parentheses are reference numbers. ACE = angiotensin- 
converting enzyme; CHF = congestive heart failure; EP = expert panel; HFH = 
data from Henry Ford Hospital; Rx = treatment. 
impact of digoxin therapy on the incidence of congestive heart 
failure exacerbations requiring medical interventions, a statistic 
that represents both a health benefit o patients who do not have 
to suffer the pain or inconvenience of such exacerbations and an 
economic benefit o the population that does not have to pay for 
the avoided medical interventions. Additional economic out- 
comes considered included the costs of digoxin, of monitoring 
serum digoxin concentration a d of treatment ofany episodes of 
digoxin toxicity. 
Assumptions. Epidemiologic assumptions. To estimate the 
magnitude of these outcomes in step 3, we made a number of 
epidemiologic assumptions based on published reports, inter- 
nal data from Henry Ford Hospital and expert opinion (Table 
1). On the basis of published estimates (17), we assumed the 
prevalence of congestive heart failure in the United States to 
be 2.5 million. We assumed the proportion of congestive heart 
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Table 2. Results of Digoxin Withdrawal Trials 
PROVED Trial (12) RADIANCE Trial (13) 
(pts not receiving ACE (pts receiving ACE 
inhibitors) inhibitors) 
Placebo Digoxin Placebo Digoxin 
(n 46) (n 42) (n - 93) (n = 85) 
Rx failures at 12 wk (excluding deaths 
unrelated to CHF) 
Change in Rx only 
Emergency department visits 
Hospital admissions 
Total 
Relative risk of Rx failures with digoxin 
Unadjusted 
Adjusted for follow-up duration 
l/I 4 11 2 
1 II 3 0 
6 3 9 2 
17 7 23 4 
0.45 0.19 
0.50 0.23 
Data presented are number of patients (pts), unless otherwise indicated. Other abbreviations a  in Table 1. 
failure patients with mild to moderate, stable congestive heart 
failure in normal sinus rhythm to be 50%. We assumed that 
-46% of these patients are currently receiving angiotensin- 
converting enzyme inhibitors on the basis of an unpublished 
analysis of billing data from a study of 1,190 patients who had 
visits or admissions for which a diagnostic ode for congestive 
heart failure was assigned and who were members of the Henry 
Ford Health System's Health Maintenance Organization. A
chart audit of 100 randomly selected patients from this group 
revealed diagnostic oding inaccuracies, uggesting that the 
true rate of angiotensin-converting e zyme inhibitor utilization 
may be higher in this managed care population. 
We used published estimates of the baseline annual inci- 
dence of hospital admissions for congestive heart failure (17) 
and derived estimates of the baseline ratios of congestive heart 
failure-related mergency department and clinic visits to ad- 
missions from the PROVED and RADIANCE studies (de- 
scribed later). 
Digoxin effectiveness. Assumptions regarding the effective- 
ness of digoxin in reducing the risk of congestive heart failure 
exacerbations were derived from data from the PROVED and 
RADIANCE studies. Both studies were multicenter, double- 
blind, placebo-controlled digoxin withdrawal trials in patients 
with stable congestive heart failure with functional class II or 
III symptoms and a left ventricular ejection fraction -<35%. In 
the RADIANCE study, patients were required to be receiving 
stable doses of angiotensin-converting e zyme inhibitors for at 
least 3 months. In the PROVED study, patients were required 
to be free of angiotensin-converting enzyme inhibitors. The 
primary outcome variables of these 12-week studies included 
overall "treatment failures," defined as a death from any cause 
or an episode of worsening congestive heart failure requiring 
medical interventions. Treatment failures were classified as to 
the type of medical interventions required: an increase in drug 
therapy, an emergency department visit or a hospital admis- 
sion. In both studies, follow-up was not continued for patients 
experiencing treatment failures, so that subsequent episodes of 
worsening congestive heart failure during the 12-week period 
were not recorded. We assumed that they would have contin- 
ued to demonstrate he same risk of subsequent treatment 
failures for the remainder of the 12-week period. Because the 
placebo groups of both studies had a longer average follow-up 
duration (PROVED 34.2 days; RADIANCE 40.3 days) than 
the digoxin groups (PROVED 31.1 days; RADIANCE 33.9 
days) among patients experiencing treatment failures, this 
assumption slightly favored the placebo group for both studies. 
The results of the two studies are summarized in Table 2. To 
estimate the effectiveness of digoxin over a full year based on 
12-week follow-up data, we assumed that digoxin would be 
75% as effective in reducing the risk of treatment failures 
during the 13- to 52-week period as during weeks 1 to 12. We 
varied this assumption during sensitivity analyses from 50% to 
100%. 
Digoxin toxicity. Little is known about the incidence of 
digoxin toxicity among patients receiving digoxin therapy in 
routine outpatient practice. Among 994 patients admitted to 
the hospital with a diagnosis of heart failure at Henry Ford 
Hospital in 1987, a total of 563 (56%) were receiving digoxin, 
and in 27 (5%) the diagnosis of digoxin intoxication was made 
by their clinicians (18). A review of medical records for these 
patients howed that only 4 patients (0.7%) could be classified 
as definitely intoxicated, and the diagnosis could not be 
excluded in a total of 20 (3.5%). In the RADIANCE and 
PROVED studies, 1 patient had digoxin toxicity among 127 
patients receiving a total of 27.1 person-years of double-blind 
digoxin therapy. These observations suggest that the incidence 
of toxicity is between 0% and 18%. For our baseline model, we 
assumed a 1% annual incidence of toxicity. For one-way 
sensitivi~ analysis, we varied this assumption from 0% to the 
incidence that would render digoxin withdrawal a cost-saving 
strategy. For a Monte Carlo multiway sensitivity analysis, we 
varied the assumption from 0.1% to 2% on the basis of expert 
opinion. 
Economic assumptions. We used estimates from Henry 
Ford Hospital and the Health Care Finance Administration to
calculate costs (in 1991 dollars) associated with digoxin therapy 
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Table 3. Balance Sheet 
Plan A: Withdraw Plan B: Continue 
Digoxin Digoxin Difference 
No. of pts with CHF meeting criteria 
Prevalence of CHF in U.S. 
Proportion meeting criteria 
No. of pts with CHF meeting criteria 
Health benefits 
CHF episodes requiring hospital admission 
CHF episodes requiring emergency visit 
CHF episodes requiring unscheduled clinic 
visit 
Health risks/harms 
Episodes of digoxln toxici~, 
Economic outcomes (milLions of dollars) 
Cost for digoxin 
Cost for serum digoxin monitoring 
Cost for CHF-rclatcd admissions 
Cost for CHF-rclatcd emergency visits 
Cost for CHF-related clinic visits 
Cost to treat episodes of dignxin toxicity" 
Net cost 
2,500,000 
51)% 
1.250,000 
270,000 132,867 137,133 
54,000 26,573 27,427 
364,500 179,370 185,130 
0 12,500 12,500 
0 75 75 
0 63 63 
1,1138 511 -527 
20 10 -10 
36 18 -19 
0 13 13 
1,094 688 -406 
Abbreviations as in Tables I and 2. 
and treatment failures (Table 1). We assumed that digoxin 
therapy costs $60/year and that serum digoxin concentration 
monitoring costs $50/year. We assumed that each clinic visit for 
congestive heart failure costs $100 and that each emergency 
visit for congestive heart failure costs $363. The emergency 
visit cost was based on the assumption that all patients with 
congestive heart failure in the emergency department would 
require a chest radiograph, electrocardiogram, digoxin serum 
concentration assay and electrolyte assays. We also assumed 
that -50% of emergency visits by patients with congestive 
heart failure would require arterial blood gas measurements, 
50% would require a complete blood count with differential, 
and 10% would require an echocardiogram. Cost estimates for 
each of these procedures, as well as for emergency room and 
professional charges were derived from Henry Ford Hospital 
data using a cost/charge ratio methodology. 
We assumed that congestive heart failure hospital admis- 
sions cost $3,844 (diagnostic related group [DRG] weight of 
1.007 times the base Medicare reimbursement ra e of $3,817). 
Although a prospective study of 69 patients admitted with 
acute left ventricular failure (19) suggested that patients taking 
digoxin and angiotensin-converting e zyme inhibitors tended 
to have a shorter hospital stay, we assumed no difference in 
length of stay between the digoxin and no-digoxin strategies. 
We assumed that the average cost to treat an episode of 
digoxin toxicity, including mild and severe cases, was $1,000, on 
the basis of expert opinion. We varied this assumption from 
$500 to $2,000 in sensitivity analyses. 
Results 
Results of the outcomes calculations for the estimated 1.2 
million adult patients with mild to moderate, stable congestive 
heart failure in the United States are presented in Table 3, 
which is designated the "balance sheet" (20). The column on 
the right shows the difference that continuation of digoxin is 
expected to make on health and economic outcomes. In the 
baseline model, we estimate that continuation ofdigoxin could 
lead to -12,500 cases of digoxin toxicity. We assumed that 
there was no direct effect of digoxin on congestive heart failure 
morbidity or mortality, but if patients continued igoxin ther- 
apy, we estimated that they would experience -185,000 fewer 
unscheduled clinic visits, -27,000 fewer emergency visits and 
-137,000 fewer hospital admissions for congestive heart fail- 
ure. We estimated the annual cost of continued digoxin 
therapy, monitoring serum digoxin concentration, and treat- 
ment for cases of digoxin toxicity to be $151 million. We 
estimated the cost of clinic and emergency visits and hospital 
admissions to be $539 million with digoxin, compared with 
almost $1.1 billion without digoxin, for a savings of $556 
million. Overall, we estimated the net savings resulting from 
continuation of digoxin to be $406 million/year, comprising 
$247 million for patients with and $159 million for those 
without angiotensin-converting e zyme inhibitor therapy. 
Sensitivity analysis. To assess the causes of uncertainty in 
these calculations, we conducted a one-way sensitivity analysis 
for each of the assumption variables. Results of these calcula- 
tions are presented inFigure 1, showing the range of values of 
the net cost of digoxin withdrawal calculated using the low and 
high values of each assumption variable. On the basis of the 
range of the net cost of digoxin withdrawal in one-way sensi- 
tivity analysis, the largest source of uncertainty came from the 
epidemiologic assumptions about he prevalence of congestive 
heart failure in the United States (range $324 million), the 
proportion of patients with congestive heart failure meeting 
the criteria previously outlined (range $365 million) and the 
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Figure 1. One-way sensitivity anal- 
ysis: annual savings with digoxin, 
millions of dollars. ACE inhib. = 
angiotensin-converting e zyme in- 
hibitor; CHF - congestive heart 
failure; pct - percent; pt patient; 
Rx = treatment; wk = week. 
% CHF patients meeting 
criteria 
Relative risk of Rx failure 
without ACE inhib, wk 1-12 
Prevalence of CHF in US 
Baseline annual risk of 
hospitadzation 
Effectiveness during wk 13-52 
relative to wk 1-12 
Relative risk of Rx failure with 
ACE inhib,wk 1-12 
Cost of CHF hospitalization 
Proportion of CHF patients on 
ACE inhibitors 
Cost of digoxin therapy per pt 
per year 
Cost of digoxin serum level 
monitoring per pt per year 
Cost of physician visit 
Annual incidence of digoxin 
toxicity 
Cost to treat average episode of 
digoxin toxicity 
Baseline emergency visits as 
pct of admits 
Baseline clinic visits per year as 
pct of admits 
Cost of CHF emergency 
department visit 
0 100 200 300 400 500 600 700 
baseline incidence of hospital admissions for patients meeting 
the criteria (range $257 million). As illustrated in Figure 2, 
significant uncertainty in the net cost of digoxin withdrawal is 
also attributable to the assumptions regarding the initial 
effectiveness of digoxin (described in terms of the relative risk 
of treatment failures with digoxin during the first 12 weeks). 
For patients receiving angiotensin-converting e zyme inhibi- 
tots, varying the assumed relative risk from 0.06 to 0.47 (the 
90% confidence interval [CI] of the RADIANCE trial results), 
the estimated net cost of digoxin withdrawal varies from $474 
million down to $307 million (range $167 million). For patients 
not receiving angiotensin-converting e zyme inhibitors, vary- 
ing the assumed relative risk from 0.21 to 0.94 (the 90% CI of 
the PROVED trial results), the estimated net cost of digoxin 
withdrawal varies from $545 million to $194 million (range 
$351 million). Additional uncertainty results from the extrap- 
olation of the RADIANCE and PROVED data from the first 
12 weeks to the rest of the year. If digoxin continued to be as 
effective during weeks 13 to 52 as during the first 12 weeks, the 
net savings from digoxin withdrawal increases to -$534 million 
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600 
Outcome: 500 
Net Cost of 400 
Digoxin 300 
Withdrawal 
(Millions of 200 
Dollars) 100 
0 i 
0°/0 
Patients Not Receiving 
~ . ~ ~ , ~  ACE Inhibitors 
Pat,ents , ~"~. . . .~ . . .~ .  , ~ 
ACE Inhibitors 
Baseline 23%J Baseline 50% I 
I I I l I I I l 
10% 20% 30°/0 40°/0 50% 60°/0 70°/0 80% 90% 100°/0 
Assumed Relative Risk of Treatment Failure With Digoxin (Week 1-12) 
Figure 2. One-way sensitivity analy- 
sis. Assumptions: relative risk of 
treatment failure with digoxin during 
weeks 1 to 12 (for patients receiv- 
ing or not receiving angiotensin- 
converting enzyme [ACE] inhibi- 
tors). 
(Fig. 3). Even if digoxin has no effect during weeks 13 to 52, a 
small net savings ($21 million) is expected to accrue. 
We found the model to be relatively insensitive to the 
assumed probability of digoxin toxicity during 1 year of ther- 
apy. As shown in Figure 4, increasing the assumed annual 
incidence of digoxin toxicity leads to a decrease in the esti- 
mated overall cost savings. However, continuation of digoxin 
remains acost-saving strategy at an assumed toxicity incidence 
of up to 33%, many times higher than the 0.1% to 2% range 
estimated by our expert panel. 
The net cost estimate was also found to be insensitive to the 
proportion of patients with congestive heart failure currently 
taking angiotensin-converting e zyme inhibitors, the baseline 
utilization of clinic and emergency visits and the individual unit 
cost assumptions. 
We also conducted a muhiway sensitivity analysis, simulta- 
neously varying all of the model assumptions using the Monte 
Carlo approach. The analysis howed that choosing different 
values for the assumptions for each of 10,000 model iterations 
can lead to a wide range of cost estimates, with a 90% range of 
certainty that extends from $106 to 822 million (Fig. 5). More 
than 99% of the model iterations yielded a net savings with 
continuation of digoxin therapy. 
Discussion 
Role of models in clinical decision making. To make 
decisions about which of a number of alternative treatment 
strategies is optimal for patients with a particular medical 
condition, it is necessary to estimate the health and economic 
outcomes that would be expected with each treatment s rategy 
(21). The ideal method of comparing the long-term outcomes 
of offering or not offering digoxin to adults with stable conges- 
tive heart failure would be to conduct a clinical trial that 
randomly assigns a large population of patients to each strat- 
egy and directly measures the health outcomes and costs for 
each patient over a long period of time (22). However, no such 
trial has been conducted to date, probably because of the great 
effort and expense involved and the long delay between the 
randomization f patients and the measurement of long-term 
outcomes. Until the results of such a trial are available, 
estimates of health and economic outcomes must be made by 
analyzing and synthesizing existing data and expert opinion. As 
with many clinical policy issues, the analysis and synthesis 
needed to make decisions about he use of digoxin for adults 
with stable congestive heart failure have so far been carried out 
using only subjective, informal methods. Clinical trials have 
been conducted to measure short-term efficacy (12,13), and 
recta-analyses have been prepared to synthesize the results of 
the trials (4). To our knowledge, no analysis has included 
explicit estimates of long-term health and economic outcomes 
expected if digoxin is offered or not offered to stable congestive 
heart failure patients. The present study offers a computerized 
mathematical model that synthesizes the results of two digoxin 
withdrawal trials, data from a large health care provider, 
information from published medical reports and expert opin- 
600 
Outcome J t  
Net Cost of 400 
Digoxin 300 
Withdrawal 
(Millions of 200 
Dollars) Baseline 75%] 100 j r  
0 I I 
0% 25% 50% 75% 100% 
Assumed Effectiveness During Week 13-52 Relative to Week 1-12 
Figure 3. One-way sensitivity analy- 
sis. Assumption: effectiveness of 
digoxin during weeks 13 to 52 rela- 
tive to weeks 1 to 12. 
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Figure 4. One-way sensitivity analy- 
sis. Assumption: annual incidence of
digoxin toxicity. 
Outcome: 
Net Cost of 
Digoxin 
Withdrawal 
(Millions of 
Dollars) 
500 
400 
300 
200 
100 
0 
-100 
0% 
Baseline 1%1 
5% 10% 15% 20% 25% 30% 
Assumed Annual Incidence of Digoxin Toxicity 
35% 
ion to make such explicit estimates of outcomes. These esti- 
mates can be used to guide decisions of clinicians and clinical 
policy makers, such as professional societies; health care 
institutions; professional practice review organizations; gov- 
ernment agencies; and payers writing practice guidelines, 
quality review criteria and reimbursement rules. In addition, 
the computerized model can be used to estimate the degree of 
uncertainty hat exists with existing information, identify spe- 
cific pieces of new information that are needed and evaluate 
the implications of new information as it becomes available. 
Implications for management of congestive heart failure. 
Even without he aid of a mathematical model, clinicians and 
writers have long recognized that he role of digitalis glycosides 
in stable congestive heart failure depends on balancing the 
potential benefits of reduced congestive heart failure morbidity 
and the potential harm of drug toxicity. A survey of 2,704 
physicians in 1986 (5) revealed that physicians who agreed that 
digitalis was more toxic in certain clinical settings were less 
likely to use the drug as the initial treatment of heart failure 
and more prone to discontinue the drug in patients with mild 
heart failure. Ninety percent of the physicians surveyed agreed 
that digitalis should be discontinued in patients with mild 
symptoms when ejection fraction or heart size was normal or 
when congestive heart failure was poorly documented. The 
survey concluded that a tendency by physicians to reserve 
digitalis for more severely affected patients with heart failure 
stems from a perception of the drug as potentially toxic. More 
recently, Jaeschke et al. (4) described the same "trade-off 
between the benefits and side effects of digoxin therapy" and 
concluded that the withdrawal of digoxin from patients with 
systolic dysfunction and moderate to severe heart failure can 
be considered a "safe and prudent measure." These clinicians 
and investigators implicitly estimated the outcomes of with- 
drawal or continuation of digoxin therapy and concluded that 
the harms exceeded the benefits among certain subgroups of 
patients with congestive heart failure. However, without ex- 
plicit estimates of outcomes based on explicitly stated logic and 
assumptions, it is impossible to evaluate these conclusions 
about digoxin withdrawal. 
The conclusiveness of this model is based on the finding 
that within a wide range of assumptions, continuation of 
digoxin is likely to lead to congestive heart failure-related 
health benefits that appear to outweigh the risk of digoxin 
toxicity and the cost of digoxin therapy. Even if we ignore any 
possible ffect of digoxin therapy on the length or quality of the 
lives of patients with congestive heart failure and assume a 1% 
Figure 5. Monte Carlo multiway 
sensitivity analysis: net annual cost of 
digoxin withdrawal. 
2,500 
2,000 
Frequency of 1,500 
Solution in 
10,000 Model 
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annual rate of digoxin toxicity, then digoxin therapy isexpected 
to eliminate 28 episodes of congestive heart failure exacerba- 
tion (11 hospital admissions, 2 emergency visits and 15 clinic 
visits) for each case of digoxin toxicity caused. Although 
individual patient preferences may vary, the magnitude of the 
benefit in relation to the risk seems ufficiently high to suggest 
that few patients would prefer the outcomes expected without 
digoxin to those expected with digoxin. Had the risks of digoxin 
therapy been much greater elative to the benefits, a sizable 
fraction of patients might prefer withdrawal of digoxin. In such 
cases, decision making can be extremely complex, reaching 
different conclusions for individual patients than for popula- 
tions of patients (23) and necessitating a more thorough 
evaluation by clinicians of the values and preferences of 
individual patients. 
The conclusiveness of this analysis also stems from the 
finding that digoxin therapy in patients with mild to moderate 
stable heart failure appears to be a "win-win" situation, with 
positive health benefits accompanied by a net cost savings. If 
the calculations indicated that net cost would increase, the 
decision would be more difficult, requiring atrade-off between 
the interests of individual patients and the interests of the 
whole population of patients erved by the health care system. 
Individual patients, particularly if they have insurance that 
covers costs, may opt for beneficial interventions regardless of 
cost. Doctors acting only as advocates for individual patients 
may do the same. But when decisions are to be made in the 
interest of the population of patients erved by the health care 
system, such as in developing practice guidelines, only inter- 
ventions that offer a benefit large enough to be considered 
"worth" the cost would be recommended. To do otherwise 
would be to allocate scarce resources ina manner that failed to 
obtain the greatest possible health benefit. Responsible clini- 
cians, perhaps from a desire to avoid waste, routinely make 
decisions based on such reasoning (21). Balance sheets like the 
one shown in Table 3 are designed to guide decisions in a more 
formal, explicit manner. However, there is not yet consensus 
about who should make such decisions, which methods hould 
be used, and what should be used as a threshold for deciding if 
the benefits of an intervention are worth the risks and costs. 
Implications for future research. As stated earlier, one of 
the benefits of a model-based clinical policy analysis is to guide 
future research, suggesting outcome variables or assumptions 
that influence decision making but for which poor information 
is presently available. The present model is based on poor 
information regarding the long-term benefits of digoxin ther- 
apy and on the incidence and consequences of digoxin toxicity 
among patients treated with digoxin on a routine ambulatory 
care basis. Sensitivity analysis revealed that the overall findings 
of the model hold true using a wide range of assumptions for 
these key variables. However, the certainty of the estimated 
magnitudes of the health and economic outcomes could be 
improved with better information about these factors. Fortu- 
nately, the National Heart, Lung, and Blood Institute and the 
Department ofVeterans Affairs Cooperative Studies Program 
are presently conducting an international, double-blind, ran- 
domized, controlled clinical trial (Digitalis Investigation 
Group [DIG]) to assess the effect of digoxin on the survival of 
patients with stable congestive heart failure, with an ejection 
fraction <-45%, who are being treated with angiotensin- 
converting enzyme inhibitors. A total of 7,790 patients have 
been randomized to receive either digoxin or placebo, with 
results available by 1996. To maximize the informational 
benefit of this costly randomization and follow-up effort, we 
recommend that in addition to physiologic outcomes and 
mortality, the study include measurements of quality of life and 
economic outcomes (costs) as well. Also, the DIG study 
represents an opportunity o provide better information about 
the incidence and consequences of digitalis toxicity, although 
such information would have to be interpreted in light of 
whether study subjects may be receiving care that differs from 
that experienced in routine practice conditions. When the DIG 
study results become available, the model described in the 
present report can serve as a basis for evaluating the implica- 
tions of the results. 
Role of angiotensin.converting enzyme inhibitors. To be 
consistent with current reality, we did not assume that all 
patients for whom angiotensin-converting e zyme inhibitors 
are indicated are actually receiving them. This analysis does 
not in any way contradict the established standard of care 
regarding the importance of angiotensin-converting e zyme 
inhibitors in patients with heart failure. The life-extending 
benefits of angiotensin-converting enzyme inhibitors have been 
repeatedly demonstrated (9-11). It is essential that clinical 
practice be updated so that patients receive angiotensin- 
converting enzyme inhibitors if indicated. If 100% of such 
patients were receiving angiotensin-converting e zyme inhibi- 
tors, the cost savings from augmentation with digoxin would be 
$535 million/year, compared to $406 million in the baseline 
model (assuming 46% angiotensin-converting e zyme inhi- 
bitor compliance) or $295 million if no patients received 
angiotensin-converting e zyme inhibitors. 
Conclusions. On the basis of available vidence and exper- 
tise, continuation of digoxin leads to increased benefits and 
decreased costs for patients with stable congestive heart fail- 
ure, and withdrawal of digoxin therapy in such patients would 
be expensive to the United States as a whole. More generally, 
we conclude that decision-analysis models can be used to 
assess the health and economic implications of the results of 
clinical trials and guide the directions of future research. 
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